PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy

Neurology. 2003 Mar 11;60(5):749-56. doi: 10.1212/01.wnl.0000049930.93113.20.

Abstract

Background: Activation of central serotonin (5-HT)1A receptors, found in high density in brainstem raphe, hippocampus, and temporal neocortex, exerts an anticonvulsant effect in various experimental seizure models. To test the hypothesis that 5-HT1A receptor binding is reduced in human epileptic foci, PET imaging was performed using the radioligand [18F]trans-4-fluoro-N-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide ([18F]FCWAY), a selective 5-HT1A receptor antagonist, in patients with temporal lobe epilepsy and normal controls.

Methods: MRI and PET were performed using [15O]water and [18F]FCWAY in 10 controls and in 12 patients with temporal lobe epilepsy confirmed on ictal video-EEG; patients also underwent [18F]fluorodeoxyglucose PET. Using quantitative PET image analysis, regional values were obtained for [18F]FCWAY volume of distribution (V), cerebral blood flow (CBF), and glucose cerebral metabolic rate (CMRglc). Hippocampal volume (HV) was also measured with MRI. [18F]FCWAY V PET and MR measures were compared within patients and controls using paired t-tests; grouped comparisons were made with two sample t-tests.

Results: Lower [18F]FCWAY V was found ipsilateral than contralateral to the epileptic focus in inferior medial (IMT) and lateral (ILT) temporal regions of patients (ILT 47.4 +/- 6.1 vs 61.8 +/- 6.1, p < 0.01; IMT 52 +/- 4.6 vs 67.0 +/- 6.0, p < 0.01). [18F]FCWAY V was 29% lower in raphe and 34% lower in the ipsilateral thalamic region of patients than controls. In ILT, mean [18F]FCWAY V asymmetry index (AI) was significantly greater than mean CBF and mean CMRglc AI. Mean [18F]FCWAY V AI in IMT was greater than mean HV AI, but the difference was not significant.

Conclusion: These findings support the hypothesis of reduced serotonin receptor binding in temporal lobe epileptic foci.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Atrophy / diagnosis
  • Cerebrovascular Circulation
  • Epilepsy, Temporal Lobe / diagnostic imaging*
  • Epilepsy, Temporal Lobe / pathology
  • Epilepsy, Temporal Lobe / physiopathology*
  • Female
  • Glucose / metabolism
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Piperazines / pharmacokinetics
  • Pyridines / pharmacokinetics
  • Receptor, Serotonin, 5-HT1A / metabolism*
  • Temporal Lobe / blood supply
  • Temporal Lobe / diagnostic imaging*
  • Temporal Lobe / metabolism*
  • Tissue Distribution
  • Tomography, Emission-Computed

Substances

  • N-(2-(4-(2-methoxyphenyl)piperazino)ethyl)-N-2-(pyridyl)-4-fluorocyclohexanecarboxamide
  • Piperazines
  • Pyridines
  • Receptor, Serotonin, 5-HT1A
  • Glucose